SS -Sjögrens syndrome 
Introduction
High-titer IgG autoantibodies to the 48 kDa La/SSB protein are a serological hallmark of primary Sjögren's syndrome (SS) but also associated with systemic lupus erythematosis (SLE) and the neonatal lupus syndrome [1] [2] [3] . La is physically linked with 60 kDa Ro/SSA (Ro60) protein in ribonucleoprotein (RNP) complexes comprising small noncoding cytoplasmic (Y) RNAs termed hYRNAs 4 that are thought to drive combined anti-Ro60/La humoral responses via T cell-dependent intermolecular determinant spreading 5 . Autoantibodies to a structurally unrelated 52 kDa Ro/SSA protein (Ro52) (also termed TRIM21) are invariably part of these linked sets but can also occur as an isolated species 6 . The physiological role of La is to serve as a termination factor for RNA polymerase III 7 and to stabilize single stranded DNA during DNA metabolism 8 . Epitope mapping of the La autoantigen in patients with primary SS has revealed three immunodominant regions: LaA (amino acids (aa)1-107); LaC (aa111-242); and LaL2/3 (aa346-408) 9 .
Autoantibodies directed against the conserved winged-helix LaA determinant 10 are of particular significance because they occur in ~100% of precipitin-positive sera and appear to arise early in the anti-La response 9, 11 ; are present at the highest concentration (mg/ml range) of any determinant 12 ; bind the analagous LaA apotope on the surface of apoptotic cells where they form IgG-immune complexes [13] [14] ; react with a conserved discontinuous epitope 15 ; and are present in sera from ~80% of mothers of children with congenital heart block 14 .
While an early study reported restricted heterogeneity and kappa light chain oligoclonality of humoral responses against recombinant fragments encompassing LaC and LaL2/3 16 , nothing is known at a molecular level about the variable (V) gene usage and V region mutational status of spontaneous human anti-La autoantibodies in patients with primary SS and degree of sharing of V region structures among anti-Ro52/Ro60/La responses. We have recently developed a proteomic method that allows near full-length protein sequencing of epitopespecific populations of autoantibodies purified from whole serum [17] [18] [19] . This approach utilizes high-resolution Orbitrap mass spectrometry (MS) and differs from traditional single cell approaches by determining the molecular signature of the secreted autoantibody proteome. Our initial studies have showed that the response against an immunodominant determinant on Ro60, termed Ro60peg, is monoclonal, IgG1 kappa-restricted and specified by a characteristic HV3-23 heavy chain and KV3-20 light chain pairing that is shared (public) among unrelated patients 17 . Likewise, responses to Ro52/TRIM21 are restricted to two public IgG1 kappa clonotypes comprising a HV3-7 or HV3-23 encoded heavy chain paired with a KV3-20 light chain 18 . Direct autoantibody sequencing has also revealed common and random somatic mutations in the heavy and light chain complementaritydetermining regions (CDRs) of these autoantibodies, consistent with antigendriven clonal selection. The aim of the current study was to determine whether humoral responses to the immunodominant LaA epitope comprise similar sets of public clonotypes and whether these share molecular signatures with antiRo52/60 autoantibody-specific proteomes. Accordingly, we have characterized serum Ig proteomes selected on LaA protein in patients with primary SS using MS and identified additional patterns of public clonotypes linking humoral anti-Ro/La autoimmunity. 
Materials and Methods

Patients and controls
Sera
Analysis of specificity of affinity purified anti-LaA by ELISA
The activity and specificity of affinity purified IgGs were determined by testing the starting serum (1:500 dilution), flow through fraction (volume normalized to the starting serum) and the eluted bound fraction (1:50 dilution) on two ELISA sets.
The first tested the specificity of the affinity purified IgG on various recombinant La fragments and native La. The various La fragments were expressed as GST fusion protein constructs prepared from the pGEX vector (New England BioLabs, MA, USA). The plates (Maxisorp; Nunc, Denmark) were coated with 5μg/mL of native La (Arotec Diagnostics, New Zealand), GST-LaA, GST-LaC (aa111-242), and GST control in 0.03M carbonate buffer (pH 8.2). Non-specific sites were blocked with 3% skim milk powder and duplicate wells were incubated with the different fractions. Bound IgG was detected with anti-human IgG conjugated with alkaline phosphatase as described previously 21 . The second ELISA set tested the affinitypurified anti-LaA sample against native Ro60 (Arotec Diagnostics), full length Ro52 expressed in a maltose binding protein (MBP) fusion construct from the pMAL vector (New England Biolabs) and MBP control.
Two-dimensional gel electrophoresis (2-DE)
Affinity-purified anti-LaA samples were precipitated using a 2-D Clean Up Kit according to the manufacturers recommendations (BioRad, CA, USA) and were analysed using 2-DE as described 17 .
Mass spectrometry (MS)
Samples were prepared for MS from either in-solution digests of affinity-purified IgGs or from heavy and light chain or intact immunoglobulin plugs excised from 2-DE gels as described 18 . Analysis of peptides was carried out in a Thermo Orbitrap XL linear ion trap mass spectrometer fitted with a nanospray source (Thermo Scientific, MA, USA) as detailed previously 18 .
Protein sequence data analysis
Database searches were first carried out with Proteome Discoverer version 1.2 (Thermo Scientific) using the Sequest algorithm against two combined databases; 
De novo sequencing and mutational analysis of purified IgGs
De novo sequencing was performed on raw data files with Peaks Studio version 5.3 (Bioinformatics Solutions, ON, Canada). As there is a large degree of sequence homology between the various Ig gene families the following strict set of rules were followed to minimize erroneous assignments of families: all spectra were manually inspected for quality; peptide lists were generated from the Peaks software program; a minimum of two framework (FR) peptides were matched back to the germline sequence; and sequence homology had to be >80% when the sequences were Ig Blasted (http://www.ncbi.nlm.nih.gov/projects/igblast) against the IMGT database. Further data refinement parameters were set in the Peaks software program; scans were merged with a retention time of 1 minute, a precursor m/z error tolerance of 10ppm and a minimum charge state of 2. Scans were filtered for a precursor mass of between 350 and 5,000 Da and a quality value of >0.65. Mutational analysis and deviations from the germline IMGT sequence were carried out using the SPIDER search tool by searching against the combined IMGT/Uniprot 2010-06 databases with the following parameters: a homology match query type; a mass error tolerance of 0.01Da; and the previously described variable modifications 18 .
Results
Isolation of monospecific anti-LaA IgG from polyclonal anti-Ro/La sera
Previously, we have developed a proteomic approach to analyze self-reactive antiRo52/Ro60 clonotypes present in human polyclonal sera [17] [18] . The first step involves affinity selection of autoantibodies specific for either an immunodominant determinant or the intact autoantigen, in this case the clinically important LaA epitope located at the NH2-terminus of La protein (Fig. 1a) .
Accordingly, anti-Ro/La-positive sera from 7 subjects with primary SS were passed over individual GST-LaA columns followed by extensive washing, and eluted IgGs confirmed as specific for LaA by analyzing starting serum, flow through and eluted fractions on Ro52/Ro60/La ELISAs (Fig. 1b,c) . In control experiments, no eluted IgG was detected after normal human sera (n = 4) or sera from primary SS patients without anti-LaA (n=2) were passed over the GST-LaA column. Furthermore, no IgGs were detected in column eluates after anti-LaA-positive sera (n=3) were passed over a sham GST column.
The anti-LaA autoantibody population is biclonal and comprises unique heavy/light chain pairings
The clonality of the affinity-purified anti-LaA samples was then assessed using high-resolution 2-DE. Under reduced conditions anti-LaA IgG resolved into several overlapping heavy chain species migrating at 55kD with a range of isoelectric points (pI) from 7 to 8.5 (Fig.2a) . These spots likely represent charge variants due to posttranslational modifications of oligoclonal species such as glycosylation, as has been observed previously for mouse monoclonal antibodies and a clonotypic anti-Ro60 autoantibody 17, [22] [23] . Light chains, evident at ~25kD, resolved into 4 equally spaced spots ranging in pI from 5.2 to 6.8, identified as IGKV3-15 (gel plugs (Fig.2b) .
De novo MS sequencing of LaA-specific clonotypic autoantibodies
In order to confirm both the clonality and heavy and light chain pairings of antiLaA IgGs as detected on gel plug digests, and determine the extent of IgV-region somatic hypermutation , we performed in-solution trypsin digests of purified antiLaA IgGs followed by combined database and de novo Orbitrap MS sequencing as described [17] [18] . This confirmed the presence of the two IgG1 heavy chain species, 
Discussion
In this study, we have determined the secreted autoantibody proteome specific for an epitope on La protein that is expressed as an apotope on the surface of apoptotic cells and available for binding of maternal anti-La in congenital heart block. A combination of affinity purification, isoelectric focusing and de novo MS sequencing identified two dominant public IgG1 kappa clonotypes in unrelated patients with primary SS: one specified by a heavy chain derived from the HV3-30 gene segment paired with a KV3-15 light chain; and the second comprising a HV3-43/KV3-20 pairing. These findings extend recent proteomic analyses of anti-Ro60 and anti-Ro52 autoantibodies that show similar properties of clonal restriction and expression of public clonotypes [17] [18] . The MS approach used herein can identify fine clonotypic specificities undetectable by routine immunoassays, and has a key advantage over human hybridoma and recombinant antibody single-cell methods in that it represents the global autoantibody repertoire against a structurally defined determinant 19 . Furthermore, the proteomic approach can readily detect expressed public clonotypes in unrelated patients without selection bias and use their molecular signatures in a targeted MS diagnostic platform 18 .
Combined data from the anti-Ro52/Ro60/La autoantibody proteomes tested thus far support a model of autoantibody production against linked protein-RNA complexes in systemic autoimmunity that is based on the utilization of a remarkably restricted set of autoreactive public B cell clonotypes, and challenge the general view that these responses are highly diversified, heterogeneous and polyclonal in outbred populations. The origin of these disease-specific, interlinked public clonotypes, that we consider hallmarks of long-term humoral autoimmunity, remains unknown. An implied corollary is that patients expressing public Ro/La-specific clonotypes share common pathways of autoimmunity to multiple determinants on Ro/La complexes. In brief, we propose that intrinsic defects in early B cell tolerance checkpoints in patients predisposed to Ro/La autoimmunity 24 may allow the emergence of low affinity germline-encoded clonotypes that preferentially use certain heavy and light chain pairings; these may be exposed in secondary lymphoid organs to Ro52/Ro60/La determinants on poorly cleared apoptotic and/or necrotic remnants and undergo clonal selection, expansion and affinity maturation in dysregulated germinal centres 25 . The role of clonal selection in the generation of these clonotypes is supported by the presence of shared and random aa replacement mutations in the CDRs of the LaA-specific clonotypic IgGs, notably those from serine to arginine or asparagine that are known to produce changes in binding affinity 26 [17] [18] . In addition to the sharing of germline-encoded structures, which suggests a role for recombinatorial bias in the generation of these linked, autoreactive species, clonotypes are specified further by shared somatic mutations consistent with the notion that they are generated through independent antigen-driven clonal selection events. It is also conceivable that presentation of clonotypic V-region determinants on MHC class II by Ro-or La-specific B cells to cognate idiotypicspecific T helper cells may in part drive determinant spreading in Ro/La humoral autoimmunity [28] [29] [30] . This receptor presentation model of autoantibody diversification provides an alternative to an intermolecular T-B cell help model based on MHC class II presentation of antigenic Ro or La peptide determinants to cognate T cells 5 . Further proteomic studies on other La epitope-selected autoantibodies will help determine whether intramolecular responses beyond LaA, in particular high affinity autoantibodies against the central LaC epitope, share public clonotypes. It will also be important to examine whether the findings for Ro/La are generalisable to other linked sets of human autoantibodies.
The affinity enrichment and MS sequencing protocol detailed herein can be used to determine IgV-region molecular signatures of secreted autoantibodies present in complex serum mixtures. In conjunction with a targeted mass spectrometry diagnostic platform that utilises Ig proteome-derived V-region surrogate peptides, it potentially represents a major advance over routine immunoassays that have dominated autoimmune serology for decades. One limitation is that the methodology does not always obtain full sequence through the diversity (D) region 18 , compounded by the marked DH segment variability of autoantibodies from patients with SLE 31 . Priority should be given to isolate autoantigen-specific cells from blood or inflamed salivary glands, using labeled Ro/La determinants or single-cell recombinant antibody techniques, potentially in combination with PCR based methods to target specific gene families utilized by secreted Ro/La-specific clonotypes. Recently published refinements of the methodology have compared mass spectra data derived from mass spectrometry-based sequencing to reference V-region databases derived from next-generation sequencing of B cell repertoires [32] [33] [34] . Finally, it may be feasible to identify specific clonotypes in whole cell proteomes of patient memory B cells and/or plasma cells by targeted mass spectrometry (which can detect a peptide in a complex sample at pg/ml sensitivity), using mutated V-region surrogate peptides derived from serum antiRo/La clonotypes. Autoantibodies were measured by enzyme-linked immunosorbent assay, with optical density (OD) <0.2 considered normal; † total IgG and rheumatoid factor (RF) were measured by nephelometry. Sequence in red text indicates peptides that could not be assigned specifically to either light chain due to a high degree of sequence homology between KV3-20 and KV3-15. CDRs are boxed.
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